Since an IDH1 mutation is well known to be associated with a better overall survival and response to chemotherapy treatment, such as temozolomide, compared to IDH1-wildtype glioma, this understanding could help to identify biological targets that could be exploited to improve patient outcomes. The gene discussed is IDH1; the disease is central nervous system cancer.